Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 14/20 | 1.00 |
| ▸ | CA2 | P00918 | 14/20 | 1.00 |
| ▸ | CA7 | P43166 | 14/20 | 1.00 |
| ▸ | CA9 | Q16790 | 14/20 | 1.00 |
| ▸ | CA4 | P22748 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8002147 | 0.79 | CA1 (0.65) | CA1CA2CA7CA9CA4 | |
| SCHEMBL24756167 | 0.77 | CA1 (0.61) | CA1CA2CA7CA9CA4 | |
| SCHEMBL4395035 | 0.75 | CA1 (1.00) | CA1CA2CA7CA9CA4 | |
| SCHEMBL21091628 | 0.74 | CA1 (0.58) | CA1CA2CA7CA9CA4 | |
| SCHEMBL19670751 | 0.74 | CA1 (0.58) | CA1CA2CA7CA9CA4 | |
| Water SCHEMBL1222259 | 0.74 | CA1 (0.96) | CA1CA2CA7CA9CA4 | |
| SCHEMBL4335218 | 0.73 | CA1 (0.58) | CA1CA2CA7CA9ALDH1A1 | |
| SCHEMBL31369142 | 0.72 | CA1 (0.56) | CA1CA2CA7CA9ALDH1A1 | |
| SCHEMBL18048115 | 0.72 | CA1 (0.56) | CA1CA2CA7CA9ALDH1A1 | |
| SCHEMBL13518527 | 0.71 | CYP3A4 (0.53) | CA1CA2CA7CA9CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001079209-A2 | DIAZAFLUORENONE IL-8 ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-10-25 | — | — | WO | claimed |
| EP-3597184-B1 | INDANONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS OR OPTICAL ISOMERS THEREOF, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES | KOREA RES INST CHEMICAL TECH (KR) | 2026-03-04 | — | — | EP | disclosed |
| EP-2722042-B1 | INDANONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS OR OPTICAL ISOMERS THEREOF, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES | KOREA RES INST CHEMICAL TECH (KR) | 2019-05-29 | — | — | EP | disclosed |
| US-9890133-B2 | Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases | KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R&D (BE) | 2018-02-13 | — | — | US | disclosed |
| US-20160297789-A1 | INDANONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS OR OPTICAL ISOMERS THEREOF, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2016-10-13 | — | — | US | disclosed |
| US-9464067-B2 | Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases | KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R & D (BE) | 2016-10-11 | — | — | US | disclosed |
| EP-2722042-A2 | INDANONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS OR OPTICAL ISOMERS THEREOF, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES | Korea Research Institute of Chemical Technology (KR) | 2014-04-23 | — | — | EP | disclosed |
| WO-2001079209-A2 | DIAZAFLUORENONE IL-8 ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
| US-5591848-A | Spiroconjugated charge-transfer dyes for optical applications | THE PENN STATE RESEARCH FOUNDATION (US) | 1997-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297789-A1 | INDANONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS OR OPTICAL ISOMERS THEREOF, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES | RNASE1, IAPP, TESK1 | CA1 2725/4885CA2 3443/4885CA7 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.